IL2 and neoplasm: TCR135-engineered CD8+ T cells were also activated by C666-1-EBNA1 tumor cells and expressed higher levels of IFN-γ, IL-2, and TNF-α than non-transduced TCRneg-CD8 T cells (Figure 4C).